- Record: found
- Abstract: not found
- Article: not found
A Randomised Comparison of Bicalutamide ('Casodex') 150 mg versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic Prostate Cancer First Report from the Scandinavian Prostatic Cancer Group Study No. 6
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To assess the efficacy and tolerability of bicalutamide 150 mg ('Casodex'(1)) as immediate
therapy, either alone or as adjuvant to treatment of curative intent, in patients
with early (T1b-T4, any N, M0) prostate cancer.